Bank of America Securities: Citi Pharmaceutical company (02359.HK) expected to continue gaining market share, target price raised to 123 Hong Kong dollars.

According to the Wise Finance APP, Bank of America Securities released a research report stating that it has raised its long-term revenue forecast for PharmaKing (02359, 603259.SH), adjusting its compound annual growth rate of earnings per share from 2025 to 2032 to 16.2%. The target price of its Hong Kong stock has been raised from 115.7 Hong Kong dollars to 123 Hong Kong dollars, and the target price of its A shares has been raised from 107.6 RMB to 114.4 RMB. Given its steady order growth and improved operational efficiency, the "buy" rating has been reiterated.